OBIO Announces Launch of OBIO CAAP® for 2019

CAAP Logo.png

Toronto, Ontario – April 3, 2019 - The Ontario Bioscience Innovation Organization (OBIO®) is proud to announce its 2019 Capital Access Advisory Program (CAAP®) and the high-potential health science companies in this year’s program.

Now in its seventh year, this year’s OBIO CAAP companies will work with OBIO and a vast network of expert advisors over the next year to achieve key goals and objectives which will position them for successful financing.  OBIO CAAP companies are advancing and accelerating the development and commercialization of therapeutics, diagnostics, medical devices and digital health products and services to benefit Ontario and global human health.

OBIO CAAP is a unique program for high-potential health science companies in Ontario. They receive personalized coaching, access to a global network of expert advisors, and strategic investor introductions that will ultimately drive fundraising success and lead to business and job growth.
— Gail Garland, OBIO President and CEO
This was an exciting year for RNA Diagnostics to be in the OBIO CAAP program. Not only did we close a ‘Series A’ round of financing, we also commenced a multi-site pivotal clinical trial of our RDA technology. Participating in the OBIO CAAP in 2018/19 gave RNA Diagnostics access to leading investors at OBIO investor summits held in Niagara-on-the-Lake and New York City. The experienced OBIO team provided timely assistance and connected me with expert advisors who provided valuable feedback on our investor collaterals and strategy. I strongly recommend the OBIO CAAP program to all scaling health science companies.
— Jeremy Bridge-Cook, CEO of RNA Diagnostics, a 2018 OBIO CAAP company

To find out more about CAAP and this year's cohort of 11 high potential companies, please read the full press release here.


2019 OBIO CAAP Companies

Cohesys

Cohesys revolutionizes bone fracture treatments with BoneTape, a novel resorbable adhesive tape for craniomaxillofacial fracture fixation.

Empirica Therapeutics

Empirica Therapeutics is developing a pipeline of innovative and transformative immunotherapies for cancers with substantial unmet need.

Marion Surgical

Marion Surgical has developed a virtual reality (VR) surgical rehearsal platform with haptics that allows practicing tomorrows surgery today.

Mediphage Bioceuticals

Mediphage Bioceuticals is developing safe, effective, and accessible gene delivery platforms to unlock the therapeutic power of personalized, redoseable genetic medicine.

RetiSpec

RetiSpec has developed a non-invasive, simple to use and inexpensive tool for detection of early Alzheimer’s disease biomarkers in the eye based on machine learning, paving the way for a widely adopted Alzheimer's screening.

Talon Pharmaceutical Services

Talon Pharmaceutical is a medicinal chemistry company developing novel drugs for difficult to treat cancers including highly aggressive forms of brain and breast cancer with poor prognosis and limited treatment options.

Qidni Labs

Qidni Labs, Inc. is developing the world's smallest blood purification system for millions of patients with kidney failure. The technology will be used as a wearable device that replaces dialysis, provides more frequent therapy and significantly improves the quality of life for kidney failure patients.

Tracery Ophthalmics

Tracery Ophthalmics Inc. is a clinical stage ocular imaging & health tech company that harnesses image-based and non-image-based health data, artificial intelligence and cloud computing for the development of new diagnostic tools and individualized therapeutic strategies for blinding eye disease, first focusing on Age Related Macular Degeneration (AMD). Tracery’s technology provides a data-driven 3-part platform for Precision Drug Development and Personalized Medicine.

Vena Medical

Vena Medical has developed the world’s smallest camera, capable of travelling through veins and arteries, changing the way physicians treat patients today, and creating a platform for brand new procedures tomorrow.